Fear over NICE guidance on prostate cancer drug

January 28, 2014 2:19 pm

It’s been claimed that thousands of men with advanced prostate cancer could be denied a new drug following guidance from NICE. NICE initially recommended for NHS funding last October but have reversed this decision. NICE have justified the decision claiming there is a lack of evidence.  Enzalutamide extends life by at least five months in men who have run out of treatment options – with some patients surviving more than 18 months. However, it will be banned for patients in England previously treated with abiraterone, another new drug currently used in advanced cases.

The pharmaletter.

January 28, 2014 2:19 pm

*/?>

Sign up to receive analysis on policy developments across our specialist sectors








Contact us

For more information about how Whitehouse can help you, please contact:

Isabella Sharp
t: +44 (0)20 7793 2536
m: +44 (0)7813 307490
isabella.sharp@whitehouseconsulting.co.uk

Viviana Spaghetti
t: +44 (0)20 7463 0668
m: +44 (0)7583 051119
viviana.spaghetti@whitehouseconsulting.co.uk

For media enquiries, please contact:
Mayar Raouf

t: +44 (0)20 7463 0698
m: +44 (0)7502 327092
mayar.raouf@whitehouseconsulting.co.uk

For general enquiries, please contact:
info@whitehouseconsulting.co.uk
t: +44 (0)20 7463 0690

Sign up for the latest news

  • * Denotes required fields
  • This field is for validation purposes and should be left unchanged.